AMP-AD Data Coordination Center

AMP-AD数据协调中心

• 批准号: 10242012
• 负责人: ANNA K GREENWOOD
• 金额: $ 243.71万
• 依托单位: SAGE BIONETWORKS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10242012
• 关键词: Address; Affect; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease risk; American; Benchmarking; Bioinformatics; Biological; Biological Models; Biological Process; Biology; Communities; Community Outreach; Complex; Computer Models; Data; Data Coordinating Center; Disease; Ecosystem; Environment; Environmental Risk Factor; Evaluation; Evaluation Research; Experimental Models; Genetic; Goals; Grant; Human; Individual; Informatics; Investments; Knowledge Portal; Lead; Medicine; Meta-Analysis; Methods; Molecular; Neurodegenerative Disorders; Outcome; Outcomes Research; Performance; Privatization; Process; Reproducibility; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Services; Sister; Source; Standardization; System; Systems Biology; Therapeutic; Training; Validation; Work; biomarker discovery; biomarker identification; causal variant; cloud based; data tools; design; differential expression; digital; drug development; drug discovery; human model; improved; insight; multiple data sources; open data; pre-clinical; prevent; programs; repository; resilience; risk variant; therapeutic target; tool; transcriptome sequencing; transcriptomics; working group

Project Summary/Abstract Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease affecting more than 5 million Americans. Despite significant investment in drug discovery and development, no therapeutic options yet exist that can prevent, slow, or cure AD. The Accelerating Medicines Partnership in Alzheimer’s Disease Target Discovery and Preclinical Validation project (AMP-AD) was designed to help address this problem by identifying candidate targets through evaluation of AD-induced changes in human molecular state on a systems level. The program uses an open science paradigm to support early, iterative integration of resources and evaluation of findings across multiple independent teams. This approach was designed to improve observations through integration of multiple data sources, to increase confidence in outcomes through transparency, reproducibility, and benchmarking of methods and to accelerate evaluation of nominated AD targets by aggregating evidence and expertise across the field. Cross-consortium activities are supported by the Data Coordination Center (DCC) led by Sage Bionetworks. Functions include resource sharing, performance of cross-team analytical projects, and coordinated evaluation across the program of research outcomes. The overarching goal of AMP- AD Data Coordinating Center is to advance the AMP-AD research program through open science practices for coordinated and integrated evaluation of AD targets. As the AMP-AD community expands in terms of people, data, and research projects, several extensions to the existing DCC services are necessary to fully support the program. These include: (a) improved mechanisms to identify resources across the expanding spectrum of projects, (b) support for biologists without informatics expertise to interpret and use AD systems biology resources, (c) mechanisms to integrate external expertise and/or resources where they are needed to advance program goals, and (d) targeted analyses that serve to bridge analytical gaps across individual projects. By combining existing services with these advancements, the DCC will work to: 1. Distribute AMP-AD systems biology assets through the AMP-AD Knowledge Portal. 2. Integrate research efforts across AMP-AD projects through cross-team analyses. 3. Expand the broader impact of AMP-AD through community outreach. The proposed work is designed to maximize the vast resources and biological insights within AMP-AD and to accelerate characterization and validation of AMP-AD targets through the open dissemination and evaluation of a set of high-confidence therapeutic targets.

项目总结/摘要 阿尔茨海默病（AD）是一种使人衰弱的神经退行性疾病，影响超过500万美国人。 尽管在药物发现和开发方面投入了大量资金，但目前还没有治疗方案可以 预防、减缓或治愈AD。加速阿尔茨海默病靶点发现的药物伙伴关系 临床前验证项目（AMP-AD）旨在通过识别 通过在系统水平上评估AD诱导的人类分子状态变化来确定候选靶点。的 该计划使用开放科学范式来支持早期的，迭代的资源整合和评估， 多个独立团队的调查结果。这种方法旨在通过以下方式改善观测 整合多个数据源，通过透明度，可重复性， 和方法的基准，并通过汇总证据加速对指定的反倾销目标的评估 和整个领域的专业知识。跨联盟活动由数据协调中心提供支持 (DCC)由Sage Bionetworks领导。功能包括资源共享、跨团队分析性能 项目，并在整个研究成果计划的协调评价。AMP的首要目标是- AD数据协调中心将通过开放科学实践推进AMP-AD研究计划， 协调和综合评价反倾销目标。随着AMP-AD社区在人员方面的扩大， 数据和研究项目，现有DCC服务的几个扩展是必要的，以充分支持 程序.这些措施包括：（a）改进各种机制，以查明日益扩大的各种资源， 项目，（B）支持没有信息学专业知识的生物学家解释和使用AD系统生物学 （c）在需要外部专门知识和（或）资源的地方整合外部专门知识和（或）资源的机制， 计划目标，以及（d）有针对性的分析，以弥补各个项目之间的分析差距。通过 结合现有的服务和这些进步，DCC将努力：1。分销AMP-AD系统 生物资产通过AMP-AD知识门户。2.整合AMP-AD项目的研究工作 通过跨团队分析。3.通过社区外展扩大AMP-AD的广泛影响。的 拟议的工作旨在最大限度地利用AMP-AD中的大量资源和生物学见解， 通过公开传播和评估，加速AMP-AD靶点的表征和验证 一系列高可信度的治疗目标。